View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 20, 2021updated 28 Oct 2021 1:05pm

Oral molnupiravir has at least 350 patients left to recruit in Phase III Covid-19 trial

As breakthrough mild-to-moderate Covid-19 cases continue to rise, all eyes are on Merck and Ridgeback Biotherapeutics’ antiviral.

By William Newton

The Phase III portion of an ongoing Phase II/III trial of Merck and Ridgeback Biotherapeutics’ molnupiravir in mild-to-moderate Covid-19 has enrolled around 1,100 to 1,200 patients of its 1,550-patient target, an investigator said. The trial could complete enrolment in one to two months, assuming worldwide infection continues to spread at its current rate.

A Merck spokesperson said the trial’s enrolment is on track; November is the company’s best guess for when the trial will have enough events for a final analysis. The placebo-controlled Phase III MOVe-OUT study has a primary endpoint of percentage of patients who are hospitalised and/or die over 29 days.

The trial is enrolling adults with laboratory-confirmed, mild-to-moderate Covid-19, and at least one risk factor associated with poor disease outcomes. Participants are randomised to either 800mg molnupiravir or placebo twice daily for five days. lists the trial’s estimated primary completion date as 8 November.

Molnupiravir has Phase IIa data showing it can reduce a patient’s viral load. Virus isolation was 1.9% in the 800mg molnupiravir group compared to 16.7% in the placebo group at day three, representing a statistically significant difference, according to a Phase IIa preprint manuscript.

Molnupiravir, an oral ribonucleoside analogue, is also being studied in the Phase III MOVe-AHEAD trial in the postexposure prophylaxis setting. Merck’s collaboration with Miami, Florida-based Ridgeback was announced in May 2020.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy